NCT02782546View on ClinicalTrials.gov

Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 30, 2017

Primary Completion Date

September 16, 2026

Study Completion Date

September 16, 2026

Conditions
Acute Myeloid Leukemia
Interventions
PROCEDURE

Graft cell infusion

-Day 0

DRUG

Tacrolimus

-GVHD prophylaxis

DRUG

Mycophenolate mofetil

-GVHD prophylaxis

DRUG

G-CSF

-Continue until neutrophil engraftment as per institutional guidelines

PROCEDURE

CIML NK cell infusion

-Day +7

DRUG

ALT-803

-Start approximately 4 hours after CIML NK cell infusion

PROCEDURE

Leukapheresis

-Day +6

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

ImmunityBio, Inc.
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

The V Foundation for Cancer Research

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

ImmunityBio, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02782546 - Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter